# A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

> **NCT05513742** · PHASE2 · COMPLETED · sponsor: **Compass Therapeutics** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** CTX-009

## Key facts

- **NCT ID:** NCT05513742
- **Lead sponsor:** Compass Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-08
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513742, "A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05513742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*